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MUCUS HYPERPRODUCTION in the airways is characteristic of all the pulmonary obstructive diseases (e.g., chronic bronchitis/ COPD, cystic fibrosis, asthma, primary ciliary dyskinesia). Its fundamental cause is thought to be an inflammation-driven proliferation of goblet cells in the superficial epithelium and of mucous cells in submucosal glands. In those diseases best understood, cystic fibrosis and extrinsic asthma, the expansion of mucin producing cells appears to result, respectively, from the hyperabsorption of liquid from airway surfaces and attendant bacterial infections (8) , and from exposure to environmental allergens and/or toxins (27, 29) . Recent work suggests that a variety of tyrosine receptor kinase (RYK)-based pathways mediate the effects of pathogenic and environmental insults in the airways to stimulate hyperplasia and/or metaplasia of mucin-secreting cells and the upregulation periodic acid-Schiff (PAS)-positive staining in the airways of mucin gene expression, or less specifically, increased PAS-positive staining in the airways (e.g., Refs. 5, 14, 15, 44) . Increased mucin gene expression and PAS staining, however, define only the very beginning of the mucin secretory pathway and the quantity of mucin stores in goblet cells, respectively. We require substantially more knowledge to understand fully the complex relationships between mucin gene transcription and translation, the mechanisms and regulation of the extensive posttranslational modifications of mucins and their packaging into vesicles and granules, and finally, the exocytic release of mucins from constitutive-like and regulated secretory pathways. Agonist regulated mucin secretion has received a fair amount of attention in recent years (18, 19, 32, 60) ; however, most of this work has focused on G protein-coupled receptor (GPCR) signaling pathways, under control conditions, rather than on factors that initiate exocytosis in an inflammatory, mucin hypersecretory environment. In the studies reported here, we examined potential intracellular tyrosine phosphorylation (Y-Pi) signaling pathways by which mucin release from goblet cells might be stimulated (see Fig. 1 ), following two general approaches.
First, recent work has shown that mucin secretion from cultured SPOC1 (1, 2, 46) and several human and non-human airway epithelial cell culture models (16, 18, 31, 32, 60) is regulated intracellularly by diacylglycerol (DAG)-and Ca 2ϩ -based pathways, with ATP and UTP, acting via apical membrane P2Y 2 receptors, representing the predominant agonists. An important action of DAG in cells is the activation of conventional and novel isoforms of protein kinase C (PKC) (see Ref. 38) , and in a wide range of goblet cell models, activation of PKC by the phorbol ester, PMA, has very consistently resulted in a stimulation of mucin secretion (18, 19, 31, 32) . In SPOC1 cells, cPKC␣, nPKC␦, ε, and , and aPKC and / are expressed, but only cPKC␣ and nPKC␦ respond to PMA by translocating in the classic fashion, from cytosol to membrane fractions (1) . Furthermore, only nPKC␦ so responded to stimulation by purinergic agonist; its translocation into the membrane fraction was dependent on the agonist concentration and correlated well with the degree of mucin secretion. More recently, however, we found (C. Ehre, L. Abdullah, Y. Zhu, C. Davis, unpublished observations) that overexpression of nPKC␦ in SPOC1 cells had no effect on the mucin secretory response, whereas cells overexpressing nPKCε exhibited an enhanced response. Similarly, mucin se-cretion was unaffected in isolated, perfused agonist-exposed tracheas of nPKC␦-deficient mice, whereas the response was nearly abolished in tracheas of nPKCε mice. In sum, these results suggest nPKCε as the active PKC isoform in agonistregulated mucin secretion; however, since the nPKC␦ isoform can be activated by Y-Pi (see Ref. 55) , in addition to DAG/ PMA and the usual cofactors (38) , there is the strong possibility that this isoform is responsive to the effects of inflammatory mediators to trigger mucin release. We therefore tested whether activation of nPKC␦ by Y-Pi induces regulated mucin secretion.
Second, most of the intracellular regulatory pathways activated by inflammatory factors and environmental insults possess component proteins that are activated by Y-Pi. For instance, mucin gene expression can be driven by bacterial pathogens interacting with RYKs (35, 51) , mucous metaand hyperplasia in the airways is driven in part by RYKs activated by IL-4, IL-13, and other cytokines (15, 50, 54) , and the effects of neutrophil elastase to stimulate mucin gene expression are likely mediated by Y-Pi signaling pathways (40, 48, 52) . In this paper we found that a general increase in Y-Pi of cellular proteins stimulated mucin secretion, and then we used a variety of well-characterized inhibitors in an attempt to define the signaling pathway(s) responsible for observed stimulation.
MATERIALS AND METHODS

Materials.
Culture medium was purchased from GibcoBRL (Gaithersburg, MD) and its supplements from Collaborative Research (Bedford, MA). Nucleotides were purchased from Boehringer-Mannheim (Indianapolis, IN). PKC isoform-specific, polyclonal antibodies generated against synthetic peptides corresponding to unique COOHterminal sequences were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), as was a monoclonal phosphotyrosine antibody (p-Tyr). The inhibitor compounds LY-294002, D-609, and U-73122 were purchased from Biomol (Plymouth Meeting, PA), and U0126, wortmannin, and RAF1 Kinase Inibitor-I were from Calbiochem (San Diego, CA). Unless specified otherwise, all other chemicals were purchased from Sigma Chemical (St. Louis, MO). Pervanadate (PV) was prepared immediately before use by combining 100 M sodium vanadate with 100 M H 2O2, in DMEM/F12 (57) .
SPOC1 cell culture and mucin assay. SPOC1 cells (3, 42) , passage 7-14, were grown as described previously (1), in 100-mm tissue culture plates or in 6-well cluster plates (Costar, Cambridge, MA). Except for cells grown solely for passaging, the medium contained 10 nM retinoic acid. Culture media were changed daily, and the cultures were used for experiments after differentiation of a mucin secreting phenotype, 17-20 days postconfluence. Media samples were assessed for mucin content by enzyme-linked lectin assay (ELLA), as described previously (3), using 100-l samples bound to 96-well highbinding microtiter plates (Costar #3590) during an overnight (4°C), or a 2-h (37°C) incubation, followed by a 1 h incubation with SBA lectin. After stopping the reaction with 4 M sulfuric acid, the optical density was determined at 490 nm (Dynatech model MR5000 microtiter plate reader; Chantilly, VA), and optical density was converted to ng mucin from standard curves using purified SPOC1 mucin applied to each microtiter plate (3) .
NHBE cell culture and mucin assay. Normal human bronchial epithelial (NHBE) cells were obtained from normal human bronchi, in accordance with Institutional Review Board-approved protocols, and grown in primary culture as described previously (23, 45) . Briefly, NHBE cells were isolated and grown on plastic culture dishes in bronchial epithelial cell growth medium (BEGM), passaged at ϳ80% confluence, and first-passage cells were seeded onto collagen-coated, 12-mm Transwell-Clear permeable supports (TCols; Costar) at 250,000 cells per support. After confluence, the cells were maintained under air-liquid interface (ALI) conditions in ALI culture medium (BEGM modified per Ref. 23 ), which was changed at the basolateral surface three times a week. NHBE cell cultures were used for experiments 4 -6 wk after confluence, when the columnar cells are well-differentiated as ciliated or goblet cells. NHBE cells used for mucin secretion experiments were carefully washed using the protocol of Kemp et al. (31) and incubated 30 min without or with secretagogue. Mucins secreted onto the culture luminal surfaces were sampled by gentle 400 l collection in DMEM/F12 and quantified by ELISA using a "subunit" antibody, which recognizes most vertebrate polymeric mucins, as described previously (manuscript submitted), following the general ELLA protocol above but using purified NHBE mucins as a standard (28) .
Western blotting/immunoprecipitation/tyrosine phosphorylation. Proteins phosphorylated on tyrosine residues were identified from whole SPOC1 cell lysates using a p-Tyr antibody. Whole cell lysates prepared and protein concentrations estimated, as previously described (2), were frozen and stored at Ϫ80°C. Within 48 h of the experiment, samples were thawed, equivalent amounts of protein (10 -20 g/lane) were resolved by 10% SDS/PAGE and electrophoretically transferred to nitrocellulose membranes, and the blots were probed with p-Tyr antibody. In studies examining the Y-Pi of nPKC␦, specifically, the isoform was first immunoprecipitated from This highly schematized and simplified scheme of cellular signaling shows G protein-coupled receptors (GPCR) (purple) and receptor tyrosine kinases (RYK) (blue) pathways that potentially affect mucin secretion. Note that the Jak/STAT and TRADD/NFKB pathways affect gene expression selectively, so would not be expected to affect mucin secretion directly or acutely. The cellular messengers known to regulate exocytosis are indicated in white on a green background. Proteins that are boxed and indicated in red were targeted by the inhibitors indicated in parentheses, to test for potential effects on mucin secretion. DAG, diacylglycol; PKC, protein kinase C.
whole cell lysates using a nPKC␦ antibody. nPKC␦ antibody (1 g) was added to cell lysates and incubated for 2 h, then Protein A agarose beads (20 l, Santa Cruz Biotechnology) were added and incubated overnight (ϳ16 h), both at 4°C with gentle shaking. The beads were collected by micro-centrifugation, 15 min at 3,000 RPM. After 3ϫ wash with ice-cold PBS, the beads were collected, resuspended in 2ϫ LSB buffer, the proteins resolved by SDS-PAGE (20 g protein/lane), transferred to nitrocellulose membranes, and the blots probed with the p-Tyr antibody. Immunoreactive proteins in all blots were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL). Films of the Western blots were digitized to 12 bits with a platform scanner at a resolution of 1,200 ϫ 1,200 dpi (UMAX Powerbook 1000), and quantified using Metamorph image processing software (Universal Imaging, Downington, PA).
RESULTS
Y-Pi of nPKC␦ and mucin secretion.
In principle, activation of nPKC␦ by Y-Pi may occur at the membrane following nPKC␦ translocation in response to DAG/PMA or agonist (6, 34) , or it may occur in the cytosol independent of translocation (39) . When activated, nPKC␦ is free to phosphorylate target proteins in sub-plasma membrane or cytosolic compartments until it is deactivated by dephosphorylation. We tested whether nPKC␦ was tyrosine phosphorylated following stimulation of SPOC1 cells with purinergic agonist or PMA, and determined whether this event correlated with stimulated mucin secretion. Figure 2A shows that the state of nPKC␦ Y-Pi changes rapidly following stimulation by agonist and PMA. In response to the application and continuous presence of ATP␥S, 1 nPKC␦ was tyrosine phosphorylated transiently, with its peak activation occurring at 1 min. By 10 min following application, the amount of nPKC␦ Y-Pi had declined approximately to control levels, and these levels continued to decline with longer periods of incubation until they were ϳ25% below control levels at 60 min.
NPKC␦ was also activated by Y-Pi following stimulation by 30 or 300 nM PMA. The lower, 30 nM concentration of PMA induces a maximal translocation response from nPKC␦ and cPKC␣ in SPOC1 cells, but mucin secretion is stimulated maximally at 300 nM (1, 46) . The two concentrations of PMA induced a Y-Pi of nPKC␦ that was essentially maximal at 10 min, with the higher concentration causing a higher level of phosphorylation, ϳ3-fold (300 nM) above control vs. ϳ2-fold (30 nM). In contrast to activation by ATP␥S, nPKC␦ Y-Pi following high PMA exposures was relatively stable: the staining intensities on Western blots at the 60 min time points were similar to or greater than those at the 5 min time point. The effects of lower PMA concentrations declined slightly from the peak.
Isoproterenol is a specific agonist for ␤-adrenergic receptors and has been shown to stimulate cAMP production in SPOC1 cells (11) , but neither SPOC1 cells nor NHBE cells response to cAMP-dependent signals with increases in mucin secretion (2, 16) . In contrast to both ATP␥S and PMA, isoproterenol caused an inhibition of nPKC␦ Y-Pi, to levels ϳ25% below control, with a time course that was both rapid and persistent. As will be appreciated from the blot in Fig. 2A , the isoproterenol data 1 ATP␥S is an analog of ATP that serves as a full agonist in whole cell responses of SPOC1 cells (3) . It is used instead of ATP or UTP in these studies because it is resistant to hydrolysis by ecto-nucleotide hydrolyzing enzymes, and because it activates P2Y2 over other purinoceptors (60) . At each time point for nPKC␦-Y-Pi determinations above, the medium was assessed by enzyme-linked lectin assay (ELLA) for mucin content. For convenience, the t ϭ 0 time points are not shown; note that the t ϭ 1 min points for all but agonist were not different from their respective controls. *P Ͻ 0.05, relative to the t ϭ 0 control at the same time point.
were rather noisy relative to those derived from the other secretagogues. The reasons for this difference in quality are not clear, but on average the data indicated that nPKC␦ Y-Pi was diminished following isoproterenol.
The effects on mucin secretion from SPOC1 cells was assessed in the same preparations used for the experiments on the time course of nPKC␦ Y-Pi (Fig. 2B) . Consistent with our previous results (1), ATP␥S and 30 nM PMA stimulated mucin secretion from these cells to approximately the same degree, and 300 nM PMA had greater effects. Note that the mucin secretory response to ATP␥S was significantly increased at 1 min, relative to controls, whereas the responses to the two levels of PMA was not different from control at the initial time point. Thereafter, the cells responded to 30 nM PMA in a similar manner to ATP␥S, with mucin secretion reaching a plateau at Ͼ10 min, whereas 300 nM PMA elicited a response that increased throughout the duration of the experiment. As expected, isoproterenol had no significant effect on mucin secretion from these cells.
Comparing Fig. 2 , A and B reveals that PMA-induced mucin secretion appeared to follow the pattern of nPKC␦ phosphorylation, i.e., both nPKC␦ Y-Pi and mucin secretion had relatively stable plateaus. For ATP␥S, in contrast, both secretion and nPKC␦ Y-Pi were elevated quickly (1 min) but then diverged, with nPKC␦ Y-Pi declining thereafter while mucin secretion rose to a plateau. Isoproterenol caused a rapid inhibition of nPKC␦ Y-Pi but had no effect on mucin secretion. These data suggest that activation of nPKC␦ by Y-Pi in SPOC1 cells may not correlate temporally with sustained mucin secretion (i.e., Ͼ1 min).
Two tyrosine kinase inhibitors were tested for effects on nPKC␦ Y-Pi elicited by ATP␥S and PMA, genistein, a nonselective tyrosine kinase inhibitor, and PP1, an inhibitor of Src family kinases (24) that also inhibits some other tyrosine kinases (56) . As shown in Fig. 3A , genistein had no effect on nPKC␦ Y-Pi by any of the activators tested, whereas PP1 dramatically reduced nPKC␦-Y-Pi induced by both ATP␥S and PMA. Neither of these compounds, however, had a significant effect on agonist-or PMA-stimulated mucin secretion from SPOC1 cells (Fig. 3B) , suggesting the absence of a relationship between activation of nPKC␦ by Y-Pi and regulated mucin secretion.
Generalized Y-Pi of cellular proteins. Since there did not appear to be a specific relationship between nPKC␦ Y-Pi and mucin secretion, we tested whether a generalized protein Y-Pi in SPOC1 cells stimulated mucin secretion. For this purpose, we used the tyrosine phosphatase inhibitor, PV (49) . As shown in Fig. 4A , treatment of SPOC1 cells with PV promoted the Y-Pi of numerous proteins in whole cell extracts with time courses that varied significantly, but none of which developed in a major way within a 1 min time frame. Generalized protein Y-Pi was increased to an obvious degree at 15 min, and by 30 min it was massive. PP1 had obvious inhibitory effects on the Y-Pi of some proteins at 1 min and on many proteins at the 15 min time point, and over longer times genistein was also effective at reducing the degree of phosphorylation (Fig. 4A,  inset) .
PV also elicited mucin secretion from SPOC1 cells, and it enhanced secretagogue induced secretion (Fig. 4B) . PV stimulated resting cells above their baseline mucin secretion rates by 5.6 Ϯ 0.7-fold, and this degree of stimulation, at least in this experiment, was similar to the effects of purinergic agonist and 30 nM PMA in the absence of PV. When cells were exposed to a combination of PV and secretagogue, the effects were additive. Notably, neither genistein nor PP1 had any significant effect on measured baseline, PV-, secretagogue-, or PV plus secretagogue-stimulated mucin release from SPOC1 cells.
Effects of other Y-Pi pathway inhibitors on PV-induced mucin secretion.
To test whether the effects of PV could be ascribed to specific effects on cellular signaling pathways other than Src kinases, we challenged each of 4 ATP␥S-or PVexposed SPOC1 cell passages to a series of widely used inhibitors, targeting a variety of key intracellular signaling pathways (see Fig. 1 ). In the experimental matrix, each inhibitor was tested at three concentrations, in half or full log increments ranging upward from a lowest concentration near the IC 50 of each compound (the data in parentheses below are for the highest concentrations tested). In these experiments (Fig. 5) , PV stimulated mucin secretion, as in the experiment for Fig. 4 , above. Note, however, that the absolute magnitude of the responses to agonist and PV were both somewhat reduced, by about 50%, compared with the data of Fig. 4 . For the Fig. 4 experiments, ATP␥S and PV stimulated relative increases in mucin secretion of 7.3 Ϯ 0.9 and 5.6 Ϯ 0.7-fold, whereas for Fig. 5 the changes were 11.3 Ϯ 2.6 and 3.8 Ϯ 0.5-fold, respectively. The difference in relative PV-induced mucin secretory responses between the two experiments (Figs. 4 and 5) could be due to variable PV concentrations generated during its preparation, variations in PV-induced protein Y-Pi of SPOC1 cells caused by tyrosine phosphatase inhibition, variable effects of Y-Pi on signaling pathways, or numerous other possibilities. Notably, in all experiments, both those presented herein as well as all our preliminary experiments, PV was as consistent in causing a significant release of mucins from SPOC1 cells release as are P2Y 2 purinergic agonists, i.e., it was only the magnitude of the PV-induced secretory responses that was variable.
The most profound inhibitory effect on PV-induced SPOC1 cell mucin secretion was observed with U-73122, a specific inhibitor of phospholipase C (PLC) (Ref. 7, Fig. 5 ): this compound abolished the mucin secretory response of SPOC1 cells to ATP␥S (⌬% ϭ Ϫ102 Ϯ 7 at 30 M), and it was nearly as effective against PV-induced mucin secretion (⌬% ϭ Ϫ88 Ϯ 18 at 30 M). The so-called PC-specific PLC inhibitor, D-609, had no measurable effect on either secretory response (data not shown).
Wortmannin, an inhibitor of PIP3 production by PI3 kinase (4, 59), also had substantial inhibitory effects on the SPOC1 cell mucin secretory response to ATP␥S and to PV. The wortmannin inhibition of the PV response (⌬% ϭ Ϫ87 Ϯ 2 at 10 M) was significantly greater than its effect on ATP␥S-induced mucin secretion (⌬% ϭ Ϫ57 Ϯ 15, 100 M, P Ͻ 0.05). LY-294002, another key PI3 kinase inhibitor (4, 59), however, had no effect on SPOC1 cells exposed to either ATP␥S (⌬% ϭ Ϫ4 Ϯ 1 at 30 M) or PV (⌬% ϭ Ϫ0 Ϯ 8 at 30 M). Because the mucin secretory response was not inhibited by both PI3 kinase-active compounds, and because we had to use concentrations of wortmannin well above its known nM IC 50 against PI3 kinase to observe any inhibition of mucin secretion, the observed effects of wortmannin are likely due to its well-known inhibition of myosin light chain kinase (4, 37) and/or PI4 kinases (4, 17, 59) .
We also tested the effects of two inhibitors of the MAP kinase pathway (Fig. 1) , RAF1 Kinase Inhibitor-I (33), and the MEK inhibitor, U0126 (20) . Neither of these inhibitors had significant effects on the ATP␥S-induced SPOC1 cell mucin secretory response. Both compounds, however, had moderate and highly variable but concentration-dependent inhibitory effects on PV-induced secretion (RAF1 kinase inhibitor-I, Fig. 5 . Effects of the phospholipase C (PLC) inhibitor, U-73122, on ATP␥S-and PV-induced mucin secretion from SPOC1 cells. The luminal medium bathing SPOC1 cells exposed for 30 min to ATP␥S or PV (both 100 M), in the absence or presence of U-73122 (3, 10, or 30 M), were tested for secreted mucins. Cells exposed to neither secretagogue nor inhibitor served as controls. Data are presented as means Ϯ SE (n ϭ 4), *P Ͻ 0.05, relative to cells exposed to secretagogue but not to inhibitor. ⌬% ϭ Ϫ53 Ϯ 36 at 10 M; U0126, ⌬% ϭ Ϫ49 Ϯ 26 at 10 M). Hence, these studies indicate that PLC and the MAP kinase pathways may mediate the effects of inflammatory stimuli acting on Y-Pi signaling pathways to stimulate regulated mucin secretion, with PLC likely representing the primary signaling pathway.
Effects of PV on NHBE cell cultures. As with any study using a cell line as its primary material, it is important to determine whether the observations have biological and clinical relevance. To this end we compared the effectiveness of purinergic agonist and PV in stimulating mucin secretion from primary cultures of NHBE cells. As shown in Fig. 6 , both ATP␥S and PV stimulated mucin release from the cultures. Similar to the SPOC1 cell experiment in Fig. 5 , the ϳ2-fold increase in mucin secretion from NHBE cell cultures exposed to PV was significant, but less than the mucins released by ATP␥S (1.91 Ϯ 0.1 vs. 3.5 Ϯ 0.5-fold) (P Ͻ 0.05, n ϭ 10, respectively). Notably, the PLC inhibitor, U-73122, abolished the effects of both ATP␥S and PV to induce mucin secretion from NHBE cultures (⌬% ϭ Ϫ101.6 Ϯ 13.5 and Ϫ110.3 Ϯ 24.6, respectively). Hence, PV stimulates mucin release from human goblet cells via a PLC-sensitive pathway, similar to SPOC1 cells.
DISCUSSION
The regulation of airway goblet cell mucin secretion has been fairly well detailed over the past two decades. In general terms, regulated mucin secretion is very similar to the regulated exocytic pathways of the endocrine secretory cells and the neuronal synaptic machinery (9, 10, 12, 58) , with an extracellular agonist initiating a cellular messenger cascade, which results in the exocytic release of secretory cargo. For airway goblet cells, the primary agonist appears to be luminal ATP or UTP interacting with apical membrane P2Y 2 purinoceptors (18, 19, 32) (45) and mucin release (Figs. 5 and 6); and 5) stimulating tracheas of nPKCε-deficient mice with agonist results in a greatly reduced mucin secretory response (manuscript submitted). This view of regulated mucin secretion, however, was developed using a classical approach of cell physiology which may not be relevant to inflammatory environments. Hence, our findings that nPKC␦ is activated in correlation with mucin secretion (1), whereas it is nPKCε, not nPKC␦ that is essential for a full agonist-induced mucin secretory response (C. Ehre, L. Abdullah, Y. Zhu, C. Davis, unpublished observations), were provocative for suggesting the possibility that nPKC␦ could be activated by Y-Pi and mediate the goblet cell mucin secretory response to inflammatory insults (40, 48, 21, 21, 53) . Implicit in this suggestion is the notion that regulation of mucin gene transcription and glycoprotein synthesis are independent of the regulated exocytic release of mucin granules; however, this is not to say that certain inflammatory pathways might not stimulate both activities (see Fig. 1 ), especially given the known Y-Pi signaling pathways operative in inflammatory cell secretion (see 43) .
Activation of NPKC␦ by Y-Pi. nPKC␦ is a novel, Ca 2ϩ -independent isoform that is unique in several respects from other PKC isoforms. A primary difference is its activation by Y-Pi, in addition to the DAG/PMA mode of activation typical of the conventional and novel PKC subfamilies (38, 41, 55) . Notably, activation of nPKC␦ by Y-Pi can take place at the plasma membrane by Src family kinases as part of GPCR-or RYK-mediated cell stimuli (6, 34) , or in the cytosol (39) , and it endows the isoform with the ability to operate independently of the plasma membrane (see Ref. 55) .
nPKC␦ has been suggested to be involved in mucin secretion from airway goblet cells activated by both purinergic agonist (1) and neutrophil elastase (40) , agents that most likely operate via GPCR and RYK pathways, respectively (18, 32, 40, 48, 52) . We first showed that nPKC␦ is tyrosine phosphorylated in SPOC1 cells as part of purinergic agonist and PMA stimulation (Fig. 2) . The onset of nPKC␦ Y-Pi in response to purinergic agonist was rapid, but transient, whereas with PMA it was slower to develop, but persistent. The mucin secretory responses to these secretagogues also differed, developing more rapidly with purinergic agonist. Significantly, the Src family kinase inhibitor, PP1, abolished nPKC␦ Y-Pi stimulated by both purinergic agonist and PMA, whereas it had no effect on the mucin secretory responses elicited by these secretagogues (Fig. 3) . Similarly, PP1 and genistein had no effect on the mucin secretory response caused by generalized PV-induced protein Y-Pi (Fig. 4) . Hence, Src family kinases are unlikely to participate in the regulation of mucin secretion, whether they are activated by GPCRs, RYKs, or other pathways. Moreover, the results indicate that nPKC␦ is also unlikely to participate in the mucin regulatory response when activated by Y-Pi. This latter conclusion is strengthened by our recent observations in SPOC1 cells overexpressing PKC isoforms and gene-targeted The luminal medium bathing NHBE cells exposed for 30 min to ATP␥S or PV (both 100 M), in the absence or presence of U-73122 (30 M), were tested for secreted mucins. Cells exposed to neither secretagogue nor inhibitor served as controls. Data are presented as means Ϯ SE (n ϭ 7), *P Ͻ 0.05, relative to cells exposed to secretagogue but not to inhibitor. mice deficient for individual PKCs. In this study, nPKCε, not nPKC␦, was essential for a full, purinergic agonist-induced tracheal mucin secretory response (C. Ehre, L. Abdullah, Y. Zhu, C. Davis, unpublished observations). Together, these studies suggest strongly that nPKC␦ is not involved in regulated mucin secretion. The data indicating activation of nPKC␦ during the goblet cell response to purinergic agonist (1) (C. Ehre, L. Abdullah, Y. Zhu, C. Davis, unpublished observations), neutrophil elastase (40, 48) , or to inflammatory mediators (21, 53) , therefore more likely relate to goblet cell mucin gene transcription (13, 22, 26, 47, 62) , mucin glycoprotein synthesis, or other mucin secretory pathway activities downstream from exocytic release.
Generalized protein Y-Pi and mucin secretion. In determining whether signaling pathways involving Y-Pi, other than those involving nPKC␦, were capable of stimulating mucin secretion from SPOC1 cells, we wished to avoid the use of known inflammatory mediators, such as TNF␣ (21) , for the uncertainties in their underlying cellular signaling paths. Rather, we used PV to stimulate a generalized Y-Pi of cellular proteins, taking advantage of its known effect to inhibit tyrosine phosphatase activity (49) . Not surprisingly, PV caused a massive increase in tyrosine phosphorylated proteins in SPOC1 cells, and it also stimulated mucin secretion of the same order of magnitude as secretagogue-induced responses (Figs. 4 and  5) . Moreover, PV also caused a similar release of mucins from NHBE cells (Fig. 6) . Notably, the experiments determined the mucins released over 30 min, a period of time too brief for significant mucin glycoprotein synthesis to complicate the secretion results.
Having achieved a mucin secretory response to cellular Y-Pi, we next tested a variety of common inhibitors to test whether specific signaling pathways might be implicated in the response (see Fig. 1 ). In these experiments, we always compared the effects of inhibitors on PV-and purinergic agonistinduced mucin secretion. Somewhat unexpectedly, several inhibitors with a rather wide spectrum of inhibitory effects in the aggregate had no effect on either PV-or agonist-induced SPOC1 cell mucin secretion, namely genistein, PP1, and LY-294002 (Figs. 3 and 4 , and see Results). These negative results indicated the likely lack of involvement of Src family kinases and PI 3 kinases in agonist or Y-Pi signaling pathways leading to goblet cells mucin secretion. Two inhibitors of the MAP kinase signaling pathway, RAF1 Kinase Inhibitor-I, and the MEK inhibitor, U0126, selectively inhibited PV-induced SPOC1 cell mucin secretion by ϳ50%. That the MAP kinase inhibitors had no effect against agonist-induced secretion suggests that the inhibition of PV-induced secretion is specific, and that inflammatory insults, which activate associated RYKs, may stimulate both goblet cell mucin biosynthesis and secretion, at least to some degree.
The most effective degree of inhibition of PV-induced SPOC1 cells mucin secretion, ϳ90%, was observed with the PLC-specific inhibitor, U-73122. Interestingly, U-73122 inhibited agonist-induced secretion even more strongly, i.e., it was totally abolished (Fig. 5) , and it also inhibited both PV-and agonist-induced secretion from NHBE cells (Fig. 6) . That PLC should be involved in agonist-induced goblet cell mucin secretion is not surprising, since P2Y 2 purinoceptors are known to couple to and activate PLC, via G␣q, with the subsequent release of IP 3 and DAG driving the cellular pathways leading to mucin granule exocytosis (see Introduction). The notion that PLC might also mediate Y-Pi signaling pathways leading to regulated mucin secretion, however, is relatively novel, although PLC-␥ has been long known to participate in RYK signal transduction (see Ref. 30) . Many recent studies have examined the role of RYKs and/or Y-Pi pathways in the regulation of airway mucin production, with a focus on mucin gene expression (for review: Refs. 5, 14, 35, 36, 61) . Studies of this type, however, consistently neglect consideration of the signals necessary to initiate release of the newly synthesized mucins. Hence, the present finding is important for the parsimonious conclusion that regulated mucin secretion is initiated by inflammatory mediators acting via RYKs activating PLC, as do GPCR-mediated signals. PLC, of course, is not a single enzyme but a family of some 13 isoforms organized in 6 different subfamilies. The four isoforms of PLC-␤ isoforms typically couple with GPCRs via G␣q and G␤␥, and the two PLC-␥ isoforms are activated by RYKs (see Refs. 25, 30) . The multiplicity of PLC isoforms, however, strengthens, rather than diminishes the central finding of this study. It emphasizes how a signaling cascade may be initiated at different sites by different signals, then proceed down a common pathway of effector molecules to ultimately stimulate mucin granule exocytosis.
In conclusion, we find that generalized protein Y-Pi stimulates mucin secretion from SPOC1 and NHBE goblet cells, suggesting that inflammatory mediators operating via Y-Pi signaling pathways, in principal, may stimulate mucin release in addition to other likely effects on the mucin secretion pathway. PLC represents the likely primary pathway mediating the effects of these agents, though the MAP kinase pathway may also be involved to some degree. Activation of nPKC␦ by Y-Pi, however, appears not to relate directly to regulated mucin secretion, even though it appears to be activated in a correlative manner to mucin secretion. Most likely, nPKC␦ is involved at points in the mucin secretory pathway upstream of the regulated exocytic release of mucins, possibly with mucin gene transcription.
